Fas/CD95 is associated with glucocorticoid-induced osteocyte apoptosis

Area of Science:

• Bone Biology
• Cellular Signaling
• Pharmacology

Background:

• Glucocorticoids, like Dexamethasone, impair bone health by affecting osteoblasts, osteoclasts, and osteocytes.
• Understanding the molecular mechanisms of Dexamethasone-induced osteocyte apoptosis is crucial for mitigating bone loss.

Purpose of the Study:

• To investigate the molecular pathways involved in Dexamethasone-induced apoptosis of osteocytes.
• To determine the role of bisphosphonates and the Fas/CD95 pathway in this process.

Main Methods:

• Utilized MLO-Y4 osteocyte cell line and primary chicken osteocytes.
• Pre-treated cells with various bisphosphonates before Dexamethasone challenge.
• Assessed apoptosis using morphological and biochemical methods; analyzed ERK and Fas pathway involvement.

Main Results:

• Dexamethasone induced osteocyte apoptosis through the Fas/CD95 death receptor and caspase 8, independent of bisphosphonate anti-resorptive effects.
• Dexamethasone-induced apoptosis involved a transient increase in phosphorylated ERK 1/2, which was blocked by an ERK inhibitor.
• Both bisphosphonates and the ERK inhibitor reduced Fas localization to the cell membrane.

Conclusions:

• Dexamethasone-induced osteocyte apoptosis is mediated by the Fas/CD95 and ERK pathways, not solely by anti-resorptive mechanisms.
• Bisphosphonates and ERK inhibition can mitigate Dexamethasone-induced osteocyte apoptosis by affecting Fas localization.
• The findings suggest potential therapeutic strategies targeting these pathways to prevent glucocorticoid-induced bone damage.